Last $9.18 USD
Change Today -0.38 / -3.97%
Volume 98.9K
LBIO On Other Exchanges
Symbol
Exchange
Stuttgart
As of 12:54 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

lion biotechnologies inc (LBIO) Snapshot

Open
$9.57
Previous Close
$9.56
Day High
$9.70
Day Low
$9.10
52 Week High
04/4/14 - $11.25
52 Week Low
11/18/14 - $4.97
Market Cap
404.7M
Average Volume 10 Days
493.7K
EPS TTM
--
Shares Outstanding
44.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LION BIOTECHNOLOGIES INC (LBIO)

Related News

No related news articles were found.

lion biotechnologies inc (LBIO) Related Businessweek News

No Related Businessweek News Found

lion biotechnologies inc (LBIO) Details

Lion Biotechnologies, Inc., a development stage biotechnology company, develops T-cells and engineered T-cells for the treatment of various cancers. The company’s lead product candidate includes a ready-to-infuse autologous T-cell therapy using tumor-infiltrating lymphocytes (TILs) for the treatment of patients with stage IV metastatic melanoma. It has a patent license agreement with the National Institutes of Health to develop and manufacture certain proprietary autologous TILs adoptive cell therapy products for the treatment of metastatic melanoma, ovarian cancer, breast cancer, and colorectal cancer; a cooperative research and development agreement with the National Institutes of Health and the National Cancer Institute to develop adoptive cell immunotherapies that destroy metastatic melanoma cells using a patient’s tumor infiltrating lymphocytes; and a process development and scale-up consulting agreement with Lonza Walkersville, Inc. to manufacture TILs. The company was formerly known as Genesis Biopharma Inc. and changed its name to Lion Biotechnologies, Inc. in September 2013. Lion Biotechnologies, Inc. was founded in 2007 and is based in Woodland Hills, California.

8 Employees
Last Reported Date: 11/13/14
Founded in 2007

lion biotechnologies inc (LBIO) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $180.0K
Compensation as of Fiscal Year 2013.

lion biotechnologies inc (LBIO) Key Developments

Lion Biotechnologies, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 08:40 AM

Lion Biotechnologies, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 08:40 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Elma S. Hawkins, Chief Executive Officer, President and Director.

Lion Biotechnologies, Inc. Appoints Ryan Maynard as a Director and Chair of the Audit Committee

Lion Biotechnologies, Inc. announced that its board of directors has appointed Ryan Maynard to serve as a director and chair of the audit committee. His appointment is effective immediately. Since 2010, Mr. Maynard has served as executive vice president and chief financial officer of Rigel Pharmaceuticals, Inc., where he previously held several senior financial positions since 2001. Most recently as senior finance manager.

Lion Biotechnologies, Inc. Enters into an Amendment to the License Agreement with United States Public Health Service

Lion Biotechnologies, Inc. previously entered into a Patent License Agreement with the National Institutes of Health, an agency of the United States Public Health Service within the Department of Health and Human Services, pursuant to which the NIH granted a non-exclusive worldwide right and license to develop and manufacture certain proprietary autologous tumor-infiltrating lymphocyte (TIL) adoptive cell therapy products for the treatment of metastatic melanoma, ovarian cancer, breast cancer, and colorectal cancer. On February 9, 2015, the company entered into an amendment to the License Agreement pursuant to which non-exclusive license to melanoma was converted into an exclusive license.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LBIO:US $9.18 USD -0.38

LBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LBIO.
View Industry Companies
 

Industry Analysis

LBIO

Industry Average

Valuation LBIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 16.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LION BIOTECHNOLOGIES INC, please visit www.genesis-biopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.